Drug
Larotaxel clinical trials
Also written XRP9881.
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2006 | 4 |
| 2007 | 1 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic Agents source
Studies
Open first, then newest update. How each study uses larotaxel is read from its arms, and is right about nine times in ten.
Testing it · 8
- Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing RegimenCompletedPhase 3SanofiNCT00417209Written as Larotaxel (XRP9881)
- Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast CancerCompletedPhase 1/2SanofiNCT00327743Written as larotaxel
- Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder CancerCompletedPhase 3SanofiNCT00625664Written as larotaxel (XRP9881)
- Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast CancerCompletedPhase 2SanofiNCT00387907Written as larotaxel (XRP9881)
- Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer PatientsCompletedPhase 2SanofiNCT00485979Written as larotaxel (XRP9881)
- XRP9881 in Combination With Trastuzumab in Metastatic Breast CancerCompletedPhase 2SanofiNCT00386685Written as larotaxel (XRP9881)
- Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine TreatmentCompletedPhase 2SanofiNCT00087958Written as XRP9881
- Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast CancerCompletedPhase 3SanofiNCT00081796Written as larotaxel (RPR109881, XRP9881)
Codes
What other systems call larotaxel · ClinicalTrials.gg INT005312
- MeSH (NLM) C531079larotaxelOne source NLM
- UNII (FDA) TWQ8K8A81YLAROTAXELConfirmed FDA, NLM, Wikidata
- Wikidata Q6489757larotaxelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48427LarotaxelOne source FDA
- DrugBank DB12984One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531079 | larotaxel | One source NLM |
| UNII (FDA) | TWQ8K8A81Y | LAROTAXEL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6489757 | larotaxel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48427 | Larotaxel | One source FDA |
| DrugBank | DB12984 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.